Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06594939 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Jun 2026 to Jun 1, 2026 · Site details revisedv8 Show 2 more changesShow less
    • Start date changed from estimate of Jun 2026 to Jun 1, 2026
    • Site details revised
  2. Start date: Mar 2026 to Jun 2026v7
  3. Start date: Jan 2026 to Mar 2026v6
  4. Start date: Oct 2025 to Jan 2026v5
  5. Start date: Jun 2025 to Oct 2025v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Dec 2024 to Jun 2025v3
  2. Secondary endpoints: details revised at 2 of 10 entriesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This single-arm, interventional phase 2 study is designed to evaluate whether the inclusion of mosunetuzumab subcutaneous and polatuzumab vedotin (Mosun-Pola) to a split-dose CHP chemotherapy backbone will improve outcomes for elderly patients with a new diagnosis of diffuse large B-cell lymphoma.
Trial Details
NCT Number NCT06594939
Lead Sponsor Medical College of Wisconsin
Conditions Diffuse Large B Cell Lymphoma (DLBCL)
Enrollment 31 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov